<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899547</url>
  </required_header>
  <id_info>
    <org_study_id>0925-0586</org_study_id>
    <secondary_id>LASRE</secondary_id>
    <nct_id>NCT01899547</nct_id>
  </id_info>
  <brief_title>Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum</brief_title>
  <acronym>LASRE</acronym>
  <official_title>Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum : A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group, Non-Inferiority Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhangzhou Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longyan Affiliated Hospital, Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and oncological feasibility of&#xD;
      laparoscopy-assisted surgery for low rectal carcinoma compared with open surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2013</start_date>
  <completion_date type="Anticipated">June 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 years disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Disease-free survival is defined as the time from date of surgery to the date of rectal cancer recurrence or metastasis or cancer-related death (locoregional or distant recurrence) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic outcomes</measure>
    <time_frame>1 week post operatively</time_frame>
    <description>Pathologic outcomes are defined as TME quality, negative CRM and negative DRM, length of proximal resection margin (PRM), length of DRM, and the number of retrieved lymph nodes.The TME quality was graded based on the criteria proposed by Nagtegaal et al. as complete, nearly complete, or incomplete.Positive resection margin, including circumferential resection margin (CRM) and distal resection margin (DRM), was defined as the presence of cancer cells within 1 mm from the cut edge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day postoperative complications</measure>
    <time_frame>1 month within operatively</time_frame>
    <description>Thirty-day postoperative complications included any complications occurring within 30 days after surgery. Postoperative complications were graded according to the Clavien-Dindo classification. Severe complications were defined as Clavien-Dindo III-V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day postoperative mortality</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>Thirty-day operative mortality is defined as deaths occurring from any cause during the first 30 postoperative days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 and 5 years post operatively</time_frame>
    <description>Overall survival is defined as the time from date of surgery to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional recurrence rate</measure>
    <time_frame>3 and 5 years post operatively</time_frame>
    <description>Locoregional recurrence was defined as the presence of any anastomotic, pelvic or perineal tumour documented by clinical and/or pathological examination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Operative time</measure>
    <time_frame>Day 1</time_frame>
    <description>Operative time is defined as the time from skin incision to the completion of skin suture.</description>
  </other_outcome>
  <other_outcome>
    <measure>Conversion to Open Surgery</measure>
    <time_frame>Day 1</time_frame>
    <description>The conversion is defined as any part of the mesorectal dissection using the traditional open surgery. The surgeon decided the conversion after considering patient safety, technical difficulties, and relevant conditions influencing the completion of TME.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Estimated blood loss will be measured according to the suction and the weight of wet gauze, and then minus the irrigation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>from the completion of the surgery till discharge from hospital</time_frame>
    <description>Duration of hospital stay measured from the day of surgery until the day of discharge from hospital.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient self-reported bladder and sexual function</measure>
    <time_frame>at postoperative 3,6 and 12 months</time_frame>
    <description>Patient self-reported bladder and sexual function as assessed by the International Prostatic Symptom Score(I-PSS©) for male and female bladder function and the International Index of Erectile Function (IIEF) Female Sexual Function Index(FSFI©) for sexual function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>at postoperative 3,6 and 12 months</time_frame>
    <description>Health related quality of life assessed by EORTC CR29 score, EORTC CR30 score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1070</enrollment>
  <condition>Rectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo laparoscopic-assisted rectal resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo conventional open rectal resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic-assisted rectal resection</intervention_name>
    <description>Arm I: Patients undergo laparoscopic-assisted rectal resection.</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional open rectal resection</intervention_name>
    <description>Arm II: Patients undergo conventional open rectal resection.</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically proven rectal adenocarcinoma&#xD;
&#xD;
          -  inferior edge of the tumor located within 5 cm from the dentate line as determined by&#xD;
             rigid proctoscopy&#xD;
&#xD;
          -  diagnosis of rectal cancer amenable to curative surgery either by anterior resection&#xD;
             or abdominoperineal resection or extralevator abdominoperineal excision&#xD;
&#xD;
          -  T3-4a,N0 or T1-4a,N1-2 treated with neoadjuvant chemoradiotherapy&#xD;
&#xD;
          -  no evidence of distant metastases&#xD;
&#xD;
          -  tumor size &lt;6cm&#xD;
&#xD;
          -  sufficient organ function&#xD;
&#xD;
          -  no contraindication to laparoscopic surgery&#xD;
&#xD;
          -  without other malignancies in medical history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concurrent or previous diagnosis of invasive cancer within 5 years&#xD;
&#xD;
          -  locally advanced cancers requiring en bloc multivisceral resection&#xD;
&#xD;
          -  intestinal obstruction&#xD;
&#xD;
          -  intestinal perforation&#xD;
&#xD;
          -  history of colorectal surgery&#xD;
&#xD;
          -  American Society of Anesthesiologists(ASA) class 4 or 5&#xD;
&#xD;
          -  pregnant or breast-feeding women&#xD;
&#xD;
          -  history of mental disorder&#xD;
&#xD;
          -  participation in another rectal cancer clinical trial relating to surgical technique&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pan Chi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University Union Hospital</investigator_affiliation>
    <investigator_full_name>Pan Chi, MD</investigator_full_name>
    <investigator_title>Chief of Department of General Surgery, Fujian Medical University Union Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

